Cover
Cover - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Mar. 28, 2023 | Jun. 30, 2022 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Document Period End Date | Dec. 31, 2022 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2022 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity File Number | 000-32363 | ||
Entity Registrant Name | CANCER CAPITAL CORP. | ||
Entity Central Index Key | 0001130889 | ||
Entity Tax Identification Number | 91-1803648 | ||
Entity Incorporation, State or Country Code | WY | ||
Entity Address, Address Line One | 2157 S. Lincoln Street | ||
Entity Address, Address Line Two | Suite 200 | ||
Entity Address, City or Town | Salt Lake City | ||
Entity Address, State or Province | UT | ||
Entity Address, Postal Zip Code | 84106 | ||
City Area Code | 801 | ||
Local Phone Number | 323-2395 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | true | ||
Elected Not To Use the Extended Transition Period | false | ||
Entity Shell Company | true | ||
Entity Public Float | $ 0 | ||
Entity Common Stock, Shares Outstanding | 6,150,000 | ||
ICFR Auditor Attestation Flag | false | ||
Auditor Firm ID | 6117 | ||
Auditor Name | Pinnacle Accountancy Group of Utah | ||
Auditor Location | Farmington, Utah |
Balance Sheets
Balance Sheets - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
CURRENT ASSETS | ||
Cash | $ 22,055 | $ 62 |
Total current assets | 22,055 | 62 |
Total assets | 22,055 | 62 |
CURRENT LIABILITIES | ||
Accounts payable - related party | 6,000 | 6,000 |
Notes payable – related party | 155,125 | 145,125 |
Notes payable | 130,275 | 97,275 |
Accrued interest – related party | 77,680 | 65,950 |
Accrued interest | 64,574 | 54,844 |
Total current liabilities | 433,654 | 369,194 |
Total liabilities | 433,654 | 369,194 |
STOCKHOLDERS' DEFICIT | ||
Common stock, $.001 par value; 20,000,000 shares authorized; 6,150,000 shares issued and outstanding | 6,150 | 6,150 |
Additional paid-in capital | 47,050 | 47,050 |
Accumulated deficit | (464,799) | (422,332) |
Total stockholders' deficit | (411,599) | (369,132) |
Total liabilities and stockholders' deficit | $ 22,055 | $ 62 |
Balance Sheets (Parenthetical)
Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 20,000,000 | 20,000,000 |
Common Stock, Shares, Issued | 6,150,000 | 6,150,000 |
Common Stock, Shares, Outstanding | 6,150,000 | 6,150,000 |
Statements of Operations
Statements of Operations - USD ($) | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement [Abstract] | ||
Revenues | ||
Operating Expenses | ||
General and administrative | 21,008 | 18,335 |
Total operating expenses | 21,008 | 18,335 |
Loss from operations | (21,008) | (18,335) |
Other income (expense) | ||
Interest expense – related party | (11,729) | (11,132) |
Interest expense | (9,730) | (7,325) |
Total other income (expense) | (21,459) | (18,457) |
Loss before income taxes | (42,467) | (36,792) |
Income tax expense | ||
Net loss | $ (42,467) | $ (36,792) |
Net loss per share – basic and diluted | $ (0.01) | $ (0.01) |
Weighted average shares outstanding – basic and diluted | 6,150,000 | 6,150,000 |
Statements of Stockholders' Def
Statements of Stockholders' Deficit - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance – December 31, 2020 at Dec. 31, 2020 | $ 6,150 | $ 47,050 | $ (385,540) | $ (332,340) |
Shares, Outstanding, Beginning Balance at Dec. 31, 2020 | 6,150,000 | |||
Net loss | (36,792) | (36,792) | ||
Balance – December 31, 2022 at Dec. 31, 2021 | $ 6,150 | 47,050 | (422,332) | (369,132) |
Shares, Outstanding, Ending Balance at Dec. 31, 2021 | 6,150,000 | |||
Net loss | (42,467) | (42,467) | ||
Balance – December 31, 2022 at Dec. 31, 2022 | $ 6,150 | $ 47,050 | $ (464,799) | $ (411,599) |
Shares, Outstanding, Ending Balance at Dec. 31, 2022 | 6,150,000 |
Statements of Cash Flows
Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Cash Flows from Operating Activities | ||
Net Loss | $ (42,467) | $ (36,792) |
Adjustment to reconcile net loss to cash used by operating activities: | ||
Expenses paid by related party | 6,000 | 6,000 |
Changes in operating assets and liabilities: | ||
Increase in accrued interest – related party | 11,730 | 11,131 |
Increase in accrued interest | 9,730 | 7,325 |
Net cash used by operating activities | (15,007) | (12,336) |
Cash Flows from Investing Activities | ||
Net cash provided by investing activities | ||
Cash Flows from Financing Activities | ||
Proceeds from notes payable | 33,000 | 11,700 |
Proceeds from notes payable – related party | 4,000 | |
Net cash provided by financing activities | 37,000 | 11,700 |
Increase (decrease) in cash | 21,993 | (636) |
Cash and cash equivalents at beginning of year | 62 | 698 |
Cash and cash equivalents at end of year | 22,055 | 62 |
Supplemental Cash Flow Information: | ||
Cash paid for interest | ||
Cash paid for income taxes | ||
Non-Cash Investing and Financing Activities | ||
Conversion of related party accounts payable into notes payable – related party | $ 6,000 | $ 6,000 |
NOTE 1 - SUMMARY OF SIGNIFICANT
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES a. Organization and Summary of Significant Accounting Policies Cancer Capital Corp. (the Company), was incorporated April 11, 1997 under the laws of the State of Nevada. The Company was originally formed for the purpose of developing an alternative medical waste treatment system. However, the Company, in December 1997, minimized this purpose and since that time its efforts have been directed more to raising capital, development of the Company’s business plan, SEC filings and other limited operations. b. Loss Per Share The computation of earnings per share of common stock is based on the weighted average number of shares outstanding at the date of the financial statements. There are no potentially dilutive common stock equivalents. For the Years Ended 2022 2021 Net Loss $ (42,467 ) $ (36,792 ) Weighted Average Number of Shares Outstanding 6,150,000 6,150,000 Basic Loss per Common Share $ (0.01 ) $ (0.01 ) c. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. d. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. e. Concentrations of Risk As of December 31, 2022, two lenders represent in excess of 95 f. Recent Accounting Pronouncements The Company has evaluated Recent Accounting Pronouncements and has determined that all such pronouncements either do not apply or their impact is insignificant to the financial statements. g. Fair Value Measurements If required by authoritative literature, the Company would account for certain assets and liabilities at fair value. The cash, accounts payable, notes payable and accrued interest have fair values that approximate their carrying values due to the short-term nature of these instruments. |
NOTE 2 - INCOME TAXES
NOTE 2 - INCOME TAXES | 12 Months Ended |
Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
NOTE 2 - INCOME TAXES | NOTE 2 - INCOME TAXES The Company follows ASC 740, “Income Taxes,” which requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company currently has no issues creating timing differences that would mandate deferred tax expense. Net operating losses would create possible tax assets in future years. Due to the uncertainty of the utilization of net operating loss carry forwards, a valuation allowance has been made to the extent of any tax benefit that net operating losses may generate. A provision for income taxes has not been made due to net operating loss carry-forwards of $ 464,799 422,332 Deferred tax assets and the valuation account are as follows: For the Years Ended 2022 2021 Deferred tax asset: Net operating loss carryforward (at 21%) $ 97,608 $ 88,690 Valuation allowance (97,608 ) (88,690 ) $ — $ — A reconciliation of amounts obtained by applying the Federal tax rate to pre-tax income to income tax benefit is as follows: For the Years Ended 2022 2021 Federal tax benefit (at 21%) $ 8,918 $ 7,727 Change in valuation allowance (8,918 ) (7,727 ) $ — $ — The Company did not have any tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase or decrease within the next 12 months. The Company includes interest and penalties arising from the underpayment of income taxes in the statements of operations in the provision for income taxes. As of December 31, 2022 and 2021, the Company had no accrued interest or penalties related to uncertain tax positions. The tax years that remain subject to examination by major taxing jurisdictions are those for the years ended December 31, 2022, 2021, 2020 and 2019. |
NOTE 3 - GOING CONCERN
NOTE 3 - GOING CONCERN | 12 Months Ended |
Dec. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
NOTE 3 - GOING CONCERN | NOTE 3 - GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has a negative working capital of $ 411,599 464,799 |
NOTE 4 - NOTES PAYABLE
NOTE 4 - NOTES PAYABLE | 12 Months Ended |
Dec. 31, 2022 | |
Debt Disclosure [Abstract] | |
NOTE 4 - NOTES PAYABLE | NOTE 4 - NOTES PAYABLE Notes payable as of December 31, 2022 and 2021 were $ 130,275 97,275 8 33,000 11,700 Accrued interest for the notes payable was $ 64,574 54,844 |
NOTE 5 - RELATED PARTY TRANSACT
NOTE 5 - RELATED PARTY TRANSACTIONS | 12 Months Ended |
Dec. 31, 2022 | |
Related Party Transactions [Abstract] | |
NOTE 5 - RELATED PARTY TRANSACTIONS | NOTE 5 - RELATED PARTY TRANSACTIONS During the years ended December 31, 2022 and 2021, the Company incurred $ 6,000 6,000 6,000 6,000 155,125 145,125 77,680 65,950 8 |
NOTE 6_ STOCKHOLDERS_ DEFICIT
NOTE 6– STOCKHOLDERS’ DEFICIT | 12 Months Ended |
Dec. 31, 2022 | |
Equity [Abstract] | |
NOTE 6– STOCKHOLDERS’ DEFICIT | NOTE 6– STOCKHOLDERS’ DEFICIT There was no stock issued during the years ended December 31, 2022 or 2021. |
NOTE 7 _ SUBSEQUENT EVENTS
NOTE 7 – SUBSEQUENT EVENTS | 12 Months Ended |
Dec. 31, 2022 | |
Subsequent Events [Abstract] | |
NOTE 7 – SUBSEQUENT EVENTS | NOTE 7 – SUBSEQUENT EVENTS The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements. |
NOTE 1 - SUMMARY OF SIGNIFICA_2
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
a. Organization and Summary of Significant Accounting Policies | a. Organization and Summary of Significant Accounting Policies Cancer Capital Corp. (the Company), was incorporated April 11, 1997 under the laws of the State of Nevada. The Company was originally formed for the purpose of developing an alternative medical waste treatment system. However, the Company, in December 1997, minimized this purpose and since that time its efforts have been directed more to raising capital, development of the Company’s business plan, SEC filings and other limited operations. |
b. Loss Per Share | b. Loss Per Share The computation of earnings per share of common stock is based on the weighted average number of shares outstanding at the date of the financial statements. There are no potentially dilutive common stock equivalents. For the Years Ended 2022 2021 Net Loss $ (42,467 ) $ (36,792 ) Weighted Average Number of Shares Outstanding 6,150,000 6,150,000 Basic Loss per Common Share $ (0.01 ) $ (0.01 ) |
c. Cash and Cash Equivalents | c. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. |
d. Use of estimates | d. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
e. Concentrations of Risk | e. Concentrations of Risk As of December 31, 2022, two lenders represent in excess of 95 |
f. Recent Accounting Pronouncements | f. Recent Accounting Pronouncements The Company has evaluated Recent Accounting Pronouncements and has determined that all such pronouncements either do not apply or their impact is insignificant to the financial statements. |
g. Fair Value Measurements | g. Fair Value Measurements If required by authoritative literature, the Company would account for certain assets and liabilities at fair value. The cash, accounts payable, notes payable and accrued interest have fair values that approximate their carrying values due to the short-term nature of these instruments. |
NOTE 1 - SUMMARY OF SIGNIFICA_3
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block] | For the Years Ended 2022 2021 Net Loss $ (42,467 ) $ (36,792 ) Weighted Average Number of Shares Outstanding 6,150,000 6,150,000 Basic Loss per Common Share $ (0.01 ) $ (0.01 ) |
NOTE 2 - INCOME TAXES (Tables)
NOTE 2 - INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
Summary of Valuation Allowance [Table Text Block] | For the Years Ended 2022 2021 Deferred tax asset: Net operating loss carryforward (at 21%) $ 97,608 $ 88,690 Valuation allowance (97,608 ) (88,690 ) $ — $ — |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | For the Years Ended 2022 2021 Federal tax benefit (at 21%) $ 8,918 $ 7,727 Change in valuation allowance (8,918 ) (7,727 ) $ — $ — |
Computation of earnings per sha
Computation of earnings per share of common stock (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Accounting Policies [Abstract] | ||
Net Loss | $ (42,467) | $ (36,792) |
Weighted Average Number of Shares Outstanding | 6,150,000 | 6,150,000 |
Basic Loss per Common Share | $ (0.01) | $ (0.01) |
NOTE 1 - SUMMARY OF SIGNIFICA_4
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) | 12 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
Concentration Risk, Percentage | 95% |
Deferred tax assets and the val
Deferred tax assets and the valuation account (Details) - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Income Tax Disclosure [Abstract] | ||
Net operating loss carryforward (at 21%) | $ 97,608 | $ 88,690 |
Valuation allowance | $ (97,608) | $ (88,690) |
Reconciliation of federal incom
Reconciliation of federal income tax rates (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | ||
Federal tax benefit (at 21%) | $ 8,918 | $ 7,727 |
Change in valuation allowance | $ (8,918) | $ (7,727) |
NOTE 2 - INCOME TAXES (Details
NOTE 2 - INCOME TAXES (Details Narrative) - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Income Tax Disclosure [Abstract] | ||
Operating Loss Carryforwards | $ 464,799 | $ 422,332 |
NOTE 3 - GOING CONCERN (Details
NOTE 3 - GOING CONCERN (Details Narrative) - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Banking Regulation, Total Capital, Actual | $ (411,599) | |
Retained Earnings (Accumulated Deficit) | $ (464,799) | $ (422,332) |
NOTE 4 - NOTES PAYABLE (Details
NOTE 4 - NOTES PAYABLE (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Debt Disclosure [Abstract] | ||
Notes Payable, Current | $ 130,275 | $ 97,275 |
Debt Instrument, Interest Rate During Period | 8% | 8% |
Proceeds from Notes Payable | $ 33,000 | $ 11,700 |
Interest Payable, Current | $ 64,574 | $ 54,844 |
NOTE 5 - RELATED PARTY TRANSA_2
NOTE 5 - RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Related Party Transactions [Abstract] | ||
Costs and Expenses, Related Party | $ 6,000 | $ 6,000 |
[custom:ConversionOfRelatedPartyAccountsPayableIntoNotePayableRelatedParty] | 6,000 | 6,000 |
[custom:NotesPayableRelatedPartiesClassifiedCurrent1-0] | 155,125 | 145,125 |
Accrued Liabilities and Other Liabilities | $ 77,680 | $ 65,950 |
Debt Instrument, Interest Rate During Period | 8% | 8% |